AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Set up an RSS feed
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The Brown University Geriatric Psychopharmacology Update back issues
|
|
Pregabalin reduces psychic and somatic symptoms of GAD in elderly patients.(Generalized Anxiety Disorder (GAD))(Clinical report)
January 1, 2009... Pregabalin (Lyrica) was found to be safe and effective in reducing psychic and somatic symptoms of generalized anxiety disorder (GAD) in elderly patients. In an 8-week double-blind, randomized, placebo-controlled trial, patients in the pregabalin group experienced decreased levels of anxiety...
rTMS shows promise for treating vascular depression.(rTMS Update)
January 1, 2009... In what are believed to be the first randomized, controlled trials on the efficacy of repetitive transcranial magnetic stimulation rTMS) to treat vascular depression (VD), investigators showed significantly greater reductions of scores on the 17-item Hamilton Depression Rating Scale (HAMD-17)...
Catatonia and mild neuroleptic malignant syndrome with long-acting risperidone.(Adverse Events)
January 1, 2009... Neuroleptic malignant syndrome (NMS) is a rare but serious and potentially fatal adverse effect presumably caused by dopamine receptor blockade associated with the use of antipsychotic agents. The incidence of NMS has been estimated to be up to 2.4% and can occur in any age group, including...
Prescribing patterns in patients recovered from bipolar disorder.(What's New in Research)
January 1, 2009... New data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) compares prescription patterns of psychotropic medications between elderly and younger patients who recovered from BD.
The data make up one of the largest studied samples of elderly BD patients...
Doxepin improves sleep in elderly adults.(What's New in Research)
January 1, 2009... Doxepin was found to be safe and effective in treating primary insomnia in elderly patients. In a randomized, doubleblind, placebo-controlled trial, doxepin at 1 mg, 3 mg, and 6 mg resulted in significant improvement in sleep maintenance that persisted throughout the night, and had a safety...